Adjuvant Tamoxifen for Early Breast Cancer
Author Information
Author(s): I. Smith
Primary Institution: Royal Marsden Hospital
Hypothesis
Does adjuvant tamoxifen improve survival rates in early breast cancer patients?
Conclusion
Tamoxifen shows a survival benefit for postmenopausal patients, but results are mixed for premenopausal patients.
Supporting Evidence
- Tamoxifen reduced the relative risk of death by 29% in patients up to 75 years old.
- The NATO trial showed a survival benefit for postmenopausal patients.
- Negative results from the Manchester trial highlight the modest overall effect of tamoxifen.
Takeaway
Tamoxifen can help some women with early breast cancer live longer, but it doesn't work the same for everyone.
Methodology
Review of multiple trials assessing the effectiveness of tamoxifen in early breast cancer treatment.
Potential Biases
Potential bias due to the exclusion of certain patient groups in trials.
Limitations
Conflicting results among different trials and the influence of chemotherapy complicate the interpretation of tamoxifen's effectiveness.
Participant Demographics
Included both premenopausal and postmenopausal women, with a focus on node-positive patients.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website